Histone deacetylase inhibitor, butyrate, attenuates lipopolysaccharide-induced acute lung injury in mice

Respiratory Research

Volumn 11, Issue , 2010, Pages

  Ni, Yun Feng ^a   Wang, Jian ^a   Yan, Xiao Long ^a   Tian, Feng ^a   Zhao, Jin Bo ^a   Wang, Yun Jie ^a   Jiang, Tao ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYRIC ACID; EOSIN; HEMATOXYLIN; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; MYELOPEROXIDASE; NITRIC OXIDE; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; BUTYRIC ACID DERIVATIVE; CYTOKINE;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; CELL NUCLEUS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASM; DRY WEIGHT; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LUNG EDEMA; LUNG HEMORRHAGE; LUNG HOMOGENATE; LUNG LAVAGE; LUNG WEIGHT; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTECTION; PROTEIN EXPRESSION; TISSUE HOMOGENATE; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; HUMAN; METABOLISM; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ACUTE LUNG INJURY; ADMINISTRATION, ORAL; ANIMALS; BUTYRATES; CYTOKINES; DISEASE MODELS, ANIMAL; HISTONE DEACETYLASE INHIBITORS; HUMANS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; TREATMENT OUTCOME;

EID: 77952482463     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-11-33     Document Type: Article

References (32)

1. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 2007, 369:1553-1565. 10.1016/S0140-6736(07)60604-7, 17482987.
2. Ulich TR, Fann MJ, Patterson PH, Williams JH, Samal B, Castillo JD, Yin S, Guo K, Remick DG. Intratracheal injection of LPS and cytokines. V. LPS induces expression of LIF and LIF inhibits acute inflammation. Am J Physiol Lung Cell Mol Physiol 1994, 267:442-446.
3. Blackwell TS, Christman JW. The role of nuclear factor-κB in cytokine gene regulation. Am J Respir Cell Mol Biol 1997, 17:3-9.
4. McIntyre RC, Pulido EJ, Bensard DD, Shames BD, Abraham E. Thirty years of clinical trials in acute respiratory distress syndrome. Crit Care Med 2000, 28:3314-3331. 10.1097/00003246-200009000-00034, 11008997.
5. Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor CB, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon CC, Chiao JH, Rifkind R, Marks PA, Scher H. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003, 9:3578-3588.
6. Richon VM, Zhou X, Rifkind RA, Marks PA. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis 2001, 27:260-264. 10.1006/bcmd.2000.0376, 11358386.
7. Leoni F, Zaliani A, Bertolini G, Porro G, Pagani P, Pozzi P, Dona G, Fossati G, Sozzani S, Azam T, Bufler P, Fantuzzi G, Goncharov I, Kim SH, Pomerantz BJ, Reznikov LL, Siegmund B, Dinarello CA, Mascagni P. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Nat Acad Sci USA 2002, 99:2995-3000. 10.1073/pnas.052702999, 122461, 11867742.
8. Chung YL, Lee MY, Wang AJ, Yao LF. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 2003, 8:707-717. 10.1016/S1525-0016(03)00235-1, 14599803.
9. Cummings JH, Pomare EW, Branch WJ, Naylor CPE, MacFarlane GT. Short chain fatty acids in human large intestine, portal, hepatic, and venous blood. Gut 1987, 28:1221-1227. 10.1136/gut.28.10.1221, 1433442, 3678950.
10. Boffa LC, Luption JR, Mariani MR, Ceppi M, Newmark HL, Scalmati A, Lipkin M. Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats. Cancer Res 1992, 52:5906-5912.
11. Heerdt BG, Houston MA, Augenlicht LH. Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines. Cancer Res 1994, 54:3288-3294.
12. Hague A, Elder DJ, Hicks DJ, Paraskeva G. Apoptosis in colorectal tumor cells: induction by the short chain fatty acids butyrate, propionate and acetate and by the bile salt deoxycholate. Int J Cancer 1995, 60:400-406. 10.1002/ijc.2910600322, 7829251.
13. Medina V, Young GP, Edmonds B, James R, Appleton S, Zalewski PD. Induction of caspase-3 protease activity and apoptosis by butyrate and another inhibitor of histone deacetylase: dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 1997, 57:3697-3707.
14. Segain JP, Bletiere DR, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottiere HM, Galmiche JP. Butyrate inhibits inflammatory responses through NF-κB inhibition: implications for Crohn's disease. Gut 2000, 47:397-403. 10.1136/gut.47.3.397, 1728045, 10940278.
15. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, Modena D, Moras ML, Pozzi P, Reznikov LL, Siegmund B, Fantuzzi G, Dinarello CA, Mascagni P. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005, 11:1-15. 10.2119/2006-00005.Dinarello, 1449516, 16557334.
16. Säemann MD, Böhmig GA, Osterreicher CH, Burtscher H, Parolini O, Diakos C, Stöckl J, Hörl WH, Zlabinger GJ. Anti-inflammatory effects of sodium butyrate on human monocytes: potent inhibition of IL-12 and up-regulation of IL-10 production. FASEB J 2000, 14:2380-2382.
17. Chakravortty D, Koide N, Kato Y, Sugiyama T, Mu MM, Yoshida T, Yokochi T. The inhibitory action of butyrate on lipopolysaccharide-induced nitric oxide production in RAW 264.7 murine macrophage cells. J Endotoxin Res 2000, 6:243-247.
18. Rahman I. Oxidative stress, transcription factors and chromatin remodelling in lung inflammation. Biochem Pharmacol 2002, 64:935-942. 10.1016/S0006-2952(02)01153-X, 12213589.
19. Iwata K, Tomita K, Sano H, Fujii Y, Yamasaki A, Shimizu E. Trichostatin A, a histone deacetylase inhibitor, down-regulates interleukin-12 transcription in SV-40-transformed lung epithelial cells. Cell Immunol 2002, 218:26-33. 10.1016/S0008-8749(02)00523-3, 12470611.
20. Choi JH, Oh SW, Kang MS, Kwon HJ, Oh GT, Kim DY. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy 2005, 35:89-96. 10.1111/j.1365-2222.2004.02006.x, 15649272.
21. Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, Gray SG, Imitola J, Duran G, Assaf B, Langley B, Khoury SJ, Stephanopoulos G, De Girolami U, Ratan RR, Ferrante RJ, Dangond F. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 164:10-21. 10.1016/j.jneuroim.2005.02.022, 15885809.
22. Baeuerle PA, Baltimore D. NF-κB: ten years after. Cell 1996, 87:13-20. 10.1016/S0092-8674(00)81318-5, 8858144.
23. Abraham E. NF-κB activation. Crit Care Med 2000, 28:100-104. 10.1097/00003246-200004001-00012, 10667506.
24. Senftleben U, Karin M. The IKK/NF-κB pathway. Crit Care Med 2002, 30:18-26.
25. Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interkeukin-1, interferon, and elastase, in patients with respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992, 145:1016-1022.
26. Park WY, Goodman RB, Steinberg KP, Ruzinski JT, Radella F, Park DR, Pugin J, Skerrett SJ, Hudson LD, Martin TR. Cytokine balance in the lungs of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2001, 164:1896-1903.
27. Goodman RB, Pugin J, Lee JS, Matthay MA. Cytokine-mediated inflammation in acute lung injury. Cytokine Growth Factor Rev 2003, 14:523-535. 10.1016/S1359-6101(03)00059-5, 14563354.
28. Chen J, Liu X, Shu Q, Li S, Luo F. Ghrelin attenuates lipopolysaccharide-induced acute lung injury through NO pathway. Med Sci Monit 2008, 14:141-146.
29. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells overexpressing angiopoietin 1. PLoS Med 2007, 4:1525-1537.
30. Yin L, Laevsky G, Giardina C. Butyrate suppression of colonocyte NF-kappa B activation and cellular proteasome activity. J Biol Chem 2001, 276:44641-44646. 10.1074/jbc.M105170200, 11572859.
31. Chakravortty D, Koide N, Kato Y, Sugiyama T, Mu MM, Yoshida T, Yokochi T. The inhibitory action of butyrate on lipopolysaccharide-induced nitric oxide production in RAW 264.7 murine macrophage cells. J Endotoxin Res 2000, 6:243-247.
32. Sartori C, Matthay MA. Alveolar epithelial fluid transport in acute lung injury: new insights. Eur Respir 2002, 20:1299-1313.